40 results on '"Mileyko V"'
Search Results
2. 39P Clinical relevance of alterations in cancer (CRAC): A DB for selecting biomarkers for molecularly matched therapy in cancer patients
3. 73P Comparison of FDA-approved and laboratory developed next generation sequencing panels in patients with advanced cancers
4. 35P Copy number variation detection from targeted amplicon-based high-throughput sequencing in clinical settings
5. 111P Leveraging in silico signatures to predict clinically actionable variants in oncogenes
6. 109P Improved accuracy of somatic variant detection from high throughput sequencing (HTS) data via site-specific noise estimation
7. 96P Use of computational algorithms to predict mutation effect in clinical setting
8. 601TiP A multicenter randomized clinical trial evaluating the negative hyperselection of patients with RAS/BRAF wild-type metastatic colorectal cancer who are eligible for anti-EGFR therapy
9. Glioblastoma: a molecular genetic portrait and modern therapeutic strategies for drug treatment
10. 13P Incidental germline findings from tumor molecular profiling for precision oncology: Is it common and how to manage?
11. Clinical application of routine comprehensive tumour molecular profiling in the management of cancer patients
12. NGS cfDNA data as a basis for the development of qPCR diagnostic systems
13. Lessons from the routine tumor molecular profiling in Russia
14. 101P - Clinical application of routine comprehensive tumour molecular profiling in the management of cancer patients
15. Design of targeted next-generation sequencing (NGS) of circulating tumour DNA (ctDNA): towards overcoming DNA
16. NGS for precision medicine in non-small cell lung cancer: Challenges and opportunities
17. 6P - NGS cfDNA data as a basis for the development of qPCR diagnostic systems
18. 20 - Design of targeted next-generation sequencing (NGS) of circulating tumour DNA (ctDNA): towards overcoming DNA
19. Human cultured cells are capable to incorporate isolated plant mitochondria loaded with exogenous DNA
20. 45PLessons from the routine tumor molecular profiling in Russia.
21. Evaluation of blood MSI burden dynamics to trace immune checkpoint inhibitor therapy efficacy through the course of treatment.
22. Multi-Institutional Evaluation of Interrater Agreement of Biomarker-Drug Pair Rankings Based on the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) and Sources of Discordance.
23. Untapped Potential of Poly(ADP-Ribose) Polymerase Inhibitors: Lessons Learned From the Real-World Clinical Homologous Recombination Repair Mutation Testing.
24. Evidence blocks for effective presentation of genomic findings at molecular tumor boards: Single institution experience.
25. Impact of the STK11/KRAS co-mutation on the response to immunotherapy in a real-world pan-cancer cohort.
26. Failure of immune checkpoint inhibitors for microsatellite instability-positive pancreatic adenocarcinoma with atypical pattern of short tandem repeat mutation.
27. Case Report: Progressive disease of BRCA2-mutant colon adenocarcinoma following talazoparib therapy.
28. Utility of public knowledge bases for the interpretation of comprehensive tumor molecular profiling results.
29. Precision oncology strategy in cetuximab-resistant ERRFI1-mutant colon cancer: case report of disease progression on afatinib.
30. Microsatellite Instability Detection: The Current Standards, Limitations, and Misinterpretations.
31. Microsatellite Instability: A Review of Molecular Epidemiology and Implications for Immune Checkpoint Inhibitor Therapy.
32. Clinical significance of molecular subtypes of gastrointestinal tract adenocarcinoma.
33. Letter to the Editor: CHEK2 I157T - Pluto Among Numerous Low-Risk Genetic Factors Requiring Discharge From a Range of Pathogenic Variants?
34. Incidental germline findings during molecular profiling of tumor tissues for precision oncology: molecular survey and methodological obstacles.
35. CRAC (Clinical Relevance of Alterations in Cancer): a Knowledge Base for the Selection of Molecularly Matched Therapy for Solid Tumors.
36. Novel bioinformatics quality control metric for next-generation sequencing experiments in the clinical context.
37. Utility of cfDNA Fragmentation Patterns in Designing the Liquid Biopsy Profiling Panels to Improve Their Sensitivity.
38. Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions.
39. Non-random fragmentation patterns in circulating cell-free DNA reflect epigenetic regulation.
40. A reliable method to concentrate circulating DNA.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.